Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 6/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91289 | 0.89 | ICMT (0.55) | ICMTCNR1CNR2RENKDM4E | |
| SCHEMBL13131385 | 0.85 | REN (0.40) | ICMTCNR1CNR2RENALDH1A1 | |
| SCHEMBL13131358 | 0.85 | REN (0.51) | ICMTCNR1CNR2RENALDH1A1 | |
| SCHEMBL13131410 | 0.84 | MCL1 (0.48) | CNR1CNR2HTR6REN | |
| SCHEMBL13131411 | 0.84 | HTR6 (0.40) | ICMTCNR1CNR2HTR6REN | |
| SCHEMBL4602445 | 0.83 | ICMT (0.44) | ICMTCNR1CNR2HTR6REN | |
| SCHEMBL13131406 | 0.83 | GSK3B (0.40) | ICMTCNR1CNR2RENALDH1A1 | |
| SCHEMBL13132252 | 0.83 | PTGER4 (0.45) | ICMTCNR1CNR2RENALDH1A1 | |
| SCHEMBL4602440 | 0.82 | ICMT (0.43) | ICMTCNR1CNR2HTR6HRH2 | |
| SCHEMBL13132254 | 0.82 | CNR1 (0.40) | ICMTCNR1CNR2RENALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8129538-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | ICMT 1604/4885CNR1 520/4885CNR2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.